www.fdanews.com/articles/176914-archerdx-illumina-to-develop-ngs-ivd-tests
ArcherDX, Illumina to Develop NGS IVD Tests
June 3, 2016
ArcherDX has entered into a co-development agreement with Illumina to develop next-generation sequencing-based in vitro diagnostic tests.
Under the deal, ArcherDX will develop a series of tests using its Anchored Multiplex PCR chemistry that will run on the Illumina MiSeqDx instrument.
“The ArcherDX-Illumina partnership enables our vision of creating a companion test aligned to the current and next generations of targeted therapies, rather than a single companion diagnostic targeting a single targeted therapy,” said ArcherDX’s CEO Jason Myers. — Anisa Jibrell